The spread of antimalarial drug resistance: A mathematical model with practical implications for ACT drug policies by Wirichada Pongtavornpinyo et al.
    1
The spread of antimalarial drug resistance: A mathematical model with  
practical implications for ACT drug policies 
 
Wirichada Pongtavornpinyo1 
Shunmay Yeung1,2,4 
Ian Hastings3 
Arjen Dondorp1,4 
Nicholas Day1,4 
Nicholas White1,4 
 
1. Mahidol – Oxford Tropical Medicine Research Unit, Faculty of Tropical 
Medicine, Mahidol University, Bangkok , Thailand 
2. Health Policy Unit, London School of Hygiene and Tropical Medicine, Keppel 
Street, London, UK 
3. Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK 
4. Centre of Clinical Vaccinology and Tropical Medicine, Churchill Hospital, 
Heading, Oxford, UK 
 
 
Most malaria-endemic countries are implementing a change in 
antimalarial drug policy to artemisinin combination therapy (ACT). The impact 
of different drug choices and implementation strategies is uncertain. A 
comprehensive model was constructed incorporating important epidemiological 
and biological factors and used to illustrate the spread of resistance in low and 
high transmission settings. The model predicts robustly that in low transmission 
settings drug resistance spreads faster than in high transmission settings, and 
that in low transmission areas ACTs slows the spread of drug resistance to a 
partner drug, especially at high coverage rates. This effect decreases 
exponentially with increasing delay in deploying the ACT and decreasing rates of 
coverage. A major obstacle to achieving the benefits of high coverage is the 
current cost of the drugs. This argues strongly for a global subsidy to make 
ACTs generally available and affordable in endemic areas. 
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For the past half-century the malaria parasites of humans have been under 
tremendous selection pressure to evolve mechanisms of resistance to the prevailing 
antimalarial drugs. Chloroquine, and increasingly sulfadoxine-pyrimethamine (SP), 
have become largely ineffective as monotherapy for the treatment of Plasmodium 
falciparum malaria in much of the world. The World Health Organization (WHO) 
now recommends artemisinin-based combination therapy (ACT) as first line treatment 
for all P. falciparum malaria in endemic areas 1. 
ACTs are efficacious, rapidly acting, well-tolerated and safe. They are 
available in various formulations which are generally given over three days. ACTs are 
effective against both asexual and early sexual parasite stages 2, and thereby reduce 
transmissibility 3,4. The contribution of reduced transmissibility of individual treated 
infections to overall transmission depends on the proportion of transmissible 
infections that are treated and the degree of ‘saturation’ in the transmission dynamics. 
So far, significant in-vivo resistance to artemisinin derivatives has not yet been 
confirmed, and stable resistance has been very difficult to produce in the laboratory 5. 
As for any combination therapy, which involves two effective drugs from different 
classes, both component drugs protect each other from the development of drug 
resistance whilst present at effective concentrations. This should prolong their useful 
lifespan provided that the individual components are not widely available as 
monotherapies 6. 
Although malaria-endemic countries are switching to ACTs with increasing 
momentum, even at prices as low as US$1 per dose they are still too costly for 
communities and governments in poorer countries (5 – 10 times higher than the prices 
of chloroquine or SP in Africa 7). Doubts have been raised about their actual 
operational effectiveness when they are implemented in “real-life” situations, where 
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infrastructures are weak, access to health care is poor, and there is widespread 
inappropriate use of antimalarial drugs 8. Although providing easy access to very low 
cost ACTs in the private sector or free ACTs in the public sector may achieve this 
aim, it has to be balanced against the costs and risks of their widespread use. In 
particular, if artemisinins are used on their own and not in co-formulation with an 
effective partner drug, then there is a much greater risk of drug resistance arising to 
this precious class of drugs. Questions remain about the choice of combination 
therapy and timing of policy change. Finally, an important additional benefit of ACTs 
in low-transmission areas is their potential ability to reduce malaria transmission and 
thus the incidence of malaria. Enthusiasm for their deployment in high transmission 
settings is tempered by the expectation that their deployment is less likely to translate 
into reduced malaria incidence in these settings. 
 
Modelling transmission dynamics and the spread of antimalarial drug resistance 
The development of drug resistance is a two-step process, the de novo or the 
initial emergence of resistance and its subsequent spread. Resistance spreads because 
of the higher reproductive rate of resistance infections in the presence of antimalarial 
drugs. In this paper, we focus on modeling the spread of resistance assuming that drug 
resistance has already emerged among the human population. Combinations prevent 
resistance by preventing de novo emergence. Modeling the de novo emergence of 
drug resistance is discussed elsewhere 9,10. 
Whilst there is a long history of modelling malaria epidemiology 11-13 (and the 
population genetics of drug resistance 10,14,15 16) none of the existing models 
incorporate all the important pharmacological, epidemiological, parasitological, and 
human behavioural factors that affect the effectiveness of drugs, the development of 
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drug resistance, and the transmission of malaria. More recent models have become 
more realistic although they were not developed primarily to study drug resistance 17-
21. We developed a complete model of the spread of antimalarial drug resistance, 
which incorporates all the important epidemiological factors, and we use it to evaluate 
different antimalarial policy options focusing on ACT deployment in low and high 
transmission settings. 
This is a data-driven model; the model parameters for mosquito dynamics, 
malaria infection in the human host (asymptomatic, symptomatic and recrudescent 
infections) and immunity functions were obtained from clinical, laboratory and 
epidemiological studies and appropriate model fitting was then performed 
(Supplementary Information A). 
At the outset, we assume a human population which has little or no exposure 
to malaria and therefore the population has no immunity to malaria. Infected 
mosquitoes bite randomly and infect humans with drug susceptible infections and a 
monotherapy is the only available treatment. As the population becomes exposed to 
malaria and gains some level of immunity, the model updates the age-stratified 
immunity of the population according to the Entomological Inoculation Rate (EIR) 
(which varies with vectorial capacity and the infective human population (see 
equation 8, Supplementary Information B)), and is allowed to run until a steady state 
is reached (Figure 1). At this point, resistance to the monotherapy is introduced and 
ACTs are deployed when resistance reaches a specified threshold. Resistance can then 
be tracked for a specified length of 10 years after steady state to gauge the impact on 
model outcomes over time. The model provides a number of outputs but we 
concentrate here on those relevant to policy. We present the proportion of infections 
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with resistant parasites, the malaria prevalence, and the incidence of malaria. Results 
of sensitivity analyses are presented in Supplementary Information C. 
 
Results 
Resistance, Transmission Intensity and ACT coverage 
We explore model consistency and model sensitivity from the Coefficient of 
Variation (CV) and Partial Rank Correlation Coefficient (PRCC) respectively through 
four baseline scenarios at two levels of transmission intensity and two levels of ACT 
coverage i.e. low transmission setting with low ACT coverage (scenario A), low 
transmission setting with high ACT coverage (scenario B), high transmission setting 
with low ACT coverage (scenario C) and high transmission with high ACT coverage 
(scenario D) (Tables A9 and A10, Supplementary Information C). ACT coverage is 
defined as the proportion of ACT treatments among all symptomatic treated 
infections. 
In the low transmission setting (EIR<1) with low ACT coverage variations in 
the estimated prevalence of malaria stay consistently high over time (CV ~ 90%) after 
the steady state is obtained, while the variation in the estimated resistance falls 
significantly by year 8 (CV ~ 9%) with resistance approaching fixation at 100% in our 
10 year time horizon. In low transmission settings with high ACT coverage, the mean 
prevalence of malaria stays below 1% over 10 years. Migration plays an important 
role in sustaining malaria. Without imported cases, malaria is readily eradicated. 
Mean resistance increases at a slower rate than in a low coverage setting, reaching 
80% in year 10. Compared to scenario A, variation in the estimated prevalence is 
slightly lower (CV ~ 75%) while variation in the rate of resistance is higher (CV > 
30%). This indicates some levels of uncertainty in the consequences of deploying a 
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high coverage of ACT on the malaria prevalence and the rate of resistance. Once 
resistance to the slowly eliminated partner drug has emerged the spread of drug 
resistance and the malaria prevalence could be slowed down only by deploying ACTs 
at a high coverage rate while the resistance prevalence is still reasonably low. 
In the low transmission setting, Vectorial Capacity (VC) was the most 
influential parameter affecting malaria prevalence (PRCC ~ 0.6), while VC (PRCC ~ 
0.7) and the proportion of treated infections (PRCC ~ 0.4) were the most influential 
parameters affecting the spread of drug resistance. 
In the high transmission setting (EIR > 100), malaria cannot be eradicated by 
antimalarial treatment of symptomatic cases alone because the major transmission 
reservoir is in asymptomatic persons who do not take antimalarial drugs. In the high 
transmission setting with low ACT coverage, malaria prevalence increases from 36% 
to 44% within 10 years due to the spread of resistance. Resistance spreads more 
slowly compared to the low transmission setting, reaching 80% in year 10. Variation 
in estimated prevalence is small (CV < 30%) while variation in the rate of resistance 
is consistently high (CV > 45%) compared to estimates in the low transmission 
setting. Both outcomes and their variations are unaltered by deploying a high 
coverage of ACT. Treatment of symptomatic infections in the high transmission 
setting has much less effect than in the low transmission setting. Consequently, the 
spread of drug resistance is driven by the fraction of the population with some 
residual antimalarial drug in their blood and not by treatment failure. 
In the high transmission setting, the parameters influencing malaria prevalence 
are the characteristics of the infection in immune subjects with untreated infections. 
These are the parasite biomass (PRCC ~ 0.4), the gametocyte switch rate (PRCC ~ 
0.4) and the duration of infection (PRCC ~ 0.3). The proportion of residual drug in the 
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population (PRCC ~ 0.9) is the dominant factor driving the spread of drug resistance 
in this setting. The strong correlation between the fraction of population with residual 
drug concentrations and the levels of resistance from this model suggests that 
controlling the use of presumptive treatment and encouraging the use of combination 
therapy with matching half-lives to reduce the selective window would slow the 
spread of resistance down within this setting. 
 
Scenario A: Effects on resistance of delaying the policy change the ACTs 
In the first scenario we consider the impact of varying the timing of switch to 
a high coverage (i.e. 85% of all symptomatic treated infections) by combining an 
artemisinin derivative with a failing partner drug (e.g. mefloquine) where the timing 
of the switch is governed by an observed prevalence of resistance to the partner drug 
in low and high transmission settings (Figure 2 and 3). 
In the low transmission setting, treatment dependent parameter values are 
given in Table A8, Supplementary Information A. The force driving resistance comes 
from two sources; the first is from symptomatic malaria infections failing treatment 
and the second is exposure of infections to residual drug taken for presumptive or 
previous malaria treatment. More than 85% of all infections are symptomatic and thus 
treated. The rate of spread of resistance is faster relatively to the high transmission 
setting where treatment failure was identified to be the main force driving the spread 
of resistance. Deploying a high coverage of effective treatment, such as an ACT, 
when the level of resistance is still low delays the spread of drug resistance, a result 
consistent with previous results from simple epidemiological models 22. 
In the high transmission settings, immunity prevents most acquired infections 
transmitting (and synergises with antimalarial drugs). Approximately 94% of all 
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infections are asymptomatic and untreated. In the absence of antimalarial treatment, 
the resistant infections have no survival advantage over the sensitive ones, and may 
have a fitness disadvantage. The main driving force for resistance is created from the 
selective filter provided by people carrying low residual concentrations of drugs, 
which protect against the establishment of new sensitive infections but not the 
resistant ones 23,24. Without this residual drug effect, the rate of resistance would be 
much lower than shown in Figure 2b. Residual drug levels come mainly from 
previous ‘presumptive’ treatments (normally for other febrile illness), and are largely 
unrelated to the peaks of parasitemia 9 and are thereby assumed to have little or no 
influence on the de novo resistance selection probability. 
Combining an artemisinin with a drug to which resistance has arisen delays 
the spread in resistance in the low transmission setting (Figure 2a and 3a) but this 
delay decreases exponentially the later the switch is made to the ACT. By contrast, in 
the high transmission setting (Figure 2b and 3b), varying the time to switch to the 
ACT has only a small impact on delaying the spread of resistance. 
 
Scenario B: Effects on artemisinin resistance of different levels of ACT coverage 
In this scenario we assume that the monotherapy is the artemisinin and that 
drug resistance emerges to the artemisinin compound, rather than to the partner drug 
in an ACT (e.g. either piperaquine or lumefantrine), which is assumed to remain 
effective (see Table A8, Supplementary Information A). This simulates the current 
scenario in places such as Cambodia where artesunate monotherapy use is widespread 
25. We assume that the switch to the combination therapy is made when the resistance 
to artemisinin is as low as 1% (Figure 4). If the switch is made very early, when there 
are still very few cases of drug resistance, then the higher the coverage with the ACT, 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
08
.1
53
9.
1 
: P
os
te
d 
24
 J
an
 2
00
8
    9
the greater is the delay in the spread of resistance. At coverage rates of >80%, the 
level of resistance to the artemisinin does not reach 50% within the time span of 10 
years. In general, the impact of ACT deployment on malaria incidence and prevalence 
is as expected. By deploying ACTs at a high coverage, the prevalence of malaria can 
be kept at a very low level over time (0.5%) and incidence is less than 50 cases per 
year, indeed in the model eradication is only prevented by the influx of malaria in 
immigrants (Figure 5). Similar to the first scenario, the impact of ACT in the high 
transmission setting is much less. 
The model shows that deploying ACT in a high transmission setting has a 
small impact on the spread of resistance and malaria prevalence. However, as one of 
the model outcomes (results not shown), treatment failure in both low and high 
transmission settings can be sustained to a low level by deploying high ACT coverage 
(25% of recrudescence compared with 10% when deploying high ACT coverage at 
year 10). In order to make an impact on malaria transmission and resistance, vector 
control strategies need to be applied to reduce the vectorial capacity. Reduction in the 
transmission intensity results in fewer infections which, as host immunity declines, 
are more likely to be symptomatic and eventually this makes malaria control by drugs 
more effective. 
 
Discussion 
A mathematical model always represents a simplified version of the true 
biological system. Complexity is traded against robustness. We have developed a 
model of suitable complexity to include all important features of malaria transmission 
and the spread of antimalarial drug resistance in P.falciparum. The model predicts 
rapid spread of drug resistance in low transmission settings, and slower spread in high 
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transmission settings. This is consistent with epidemiological observations. In low 
transmission settings a higher proportion of potentially transmissible infections are 
exposed to antimalarial drugs and lower immunity increases the individual probability 
of treatment failure and transmission of resistant parasites. In low transmission 
settings, the spread of drug resistance can be slowed by combination treatments in 
which two or more effective drugs, which do not share resistance mechanisms, are 
combined. ACTs are currently the combinations of choice. This switch to 
combination treatment needs to be made early in the evolution of drug resistance with 
high rates of coverage (> 80%) if the full benefits in terms of delaying resistance are 
to be realised. This is the case whether the monotherapy to which resistance arises is 
an artemisinin derivative, or a non-artemisinin drug. The structure of this model 
allows many other policy relevant questions related to malaria control (vector 
controls, drug adherence and intermittent presumptive treatments etc) to be addressed. 
However, as a population based model, the ability to assess the effects of individual 
variation and the incorporation of important pharmacokinetic and pharmacodynamic 
variables is limited. 
In low transmission settings increasing ACT coverage is essential if the 
dramatic effects on malaria incidence observed recently in Northwest Thailand, 
KwaZulu Natal and Zanzibar are to be extended to other areas 26,27. P. falciparum 
malaria can be eliminated, although microheterogeneities in transmission intensity in 
remote areas will often ensure a protracted “end–game”. The impact of ACTs on drug 
resistance in high transmission intensity settings is limited because the majority of 
population are immune, many infections are asymptomatic, and therefore a smaller 
proportion of the infections are treated. An important weakness in our understanding 
of the epidemiology of malaria is the relative contribution of asymptomatic and 
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symptomatic infections to transmission. The smaller the contribution of asymptomatic 
infections, the greater is the effect of ACTs in slowing resistance spread. The main 
force driving the spread of drug resistance in these circumstances is the 
chemoprophylactic effect of presumptive therapy, which provides a selective filter for 
resistant parasites. The model also predicts that at low transmission intensities malaria 
transmission is readily eradicated without the continued influx of infected migrants. 
This has important implications for eliminating malaria 28,29. 
The question of whether it is possible to reduce malaria transmission 
sufficiently to eliminate malaria eventually in high malaria transmission areas remains 
unresolved 8. In high transmission settings, this model predicts that high ACT 
coverage alone cannot reduce malaria transmission unless it is used together with 
vector-control measures i.e. use of insecticides and deployment of insecticide-treated 
bednets (ITN) and other materials to reduce the force of infection. To overcome the 
obstacles to high coverage of the unaffordability and unavailability of ACTs, it has 
been argued persuasively that provision of global subsidies for co-formulated ACTs 
must be provided at the top of the distribution chain. This would facilitate 
considerably the flow of drugs down to the end users through the existing public and 
private sector distribution pathways, with the ultimate objective of making effective 
antimalarial treatments available and affordable even to the poorest people 30. 
Stabilizing demand for ACT would also create incentives for ACT production, 
resulting in lower prices 7. 
 
Methods 
Model development and parameter estimation 
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We model transmission and antimalarial drug resistance using a dynamic, age-
structured population-based model where the introduction of new imported (migrant) 
infections varies stochastically each day. At the end of each iteration, the inoculation 
rate for the human population is calculated from the infective contact with vectors and 
host susceptibility, based on the formula given by Dietz 31 (see equation 1, 
Supplementary Information B). The human infectiousness of infected Anopheline 
mosquito feeds is estimated from the non-linear relationship between gametocyte 
density and the chance of infecting mosquitoes, formula given by Jeffery and Eyles 32 
(see equation 5, Supplementary Information B). The average gametocytemia depends 
on the average parasite biomass by age group and the estimated gametocyte switch 
rate (i.e. probability that an asexual parasite develops to a sexual parasite). The size 
and age-structure of the human population was assumed to be constant over time in 
the model and was based on an average African age-structure (http://esa.un.org/unpp). 
The model handles malaria like a “macro” parasite by quantifying the density 
of infection in the human host. The in-vivo effect of drugs on parasite density can be 
measured, allowing quantification of the pharmacodynamic properties of antimalarial 
drugs 33. Different multiple linear and non-linear regressions equations as a function 
of age and EIR were fitted to data from age-stratified epidemiological studies in areas 
with different transmission intensities. Stepwise selection using the Akaike 
Information Criteria (AIC) was used to identify the best fit in the case of non-nested 
functions and the maximum-likelihood ratio test was used for nested functions. These 
relationships represent the development of immunity with age and malaria exposures. 
Different facets of malaria immunity are incorporated into this model (Figure 6) i.e. 
reducing host susceptibility to infection 34,35, reducing the level of (largely 
asymptomatic) parasitemia in infected people 36,37, reducing the likelihood of fever 
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and other symptoms in infected patients 38-40, reducing the treatment failure rate for a 
particular level of antimalarial drug resistance 41-46, and increasing the recovery rate of 
an established infection i.e. shortening the duration of infection 47-49 (Table A7, 
Supplementary Information A). Some immunity functions were not measured directly 
from epidemiological studies (i.e. host susceptibility, duration of infections and 
treatment failure), so a normalized function of age-stratified parasite density was used 
to estimate the relationship between age and host susceptibility and between age and 
duration of infections by specifying initially the “maximum host susceptibility” in a 
non-immune person and the “maximum duration” of treated and untreated infections. 
The host susceptibility and the duration of infection for any given age group in any 
transmission intensity setting are then determined by the shape of the immunity curve. 
As the shape of the age effect on treatment failure is similar to the relationship 
between age and severe malaria 41, we apply the same technique to the normalized 
function of age-stratified risk of severe malaria to adjust the treatment failure rates for 
any given age group in any transmission intensity setting. The maximum value of 
duration of infection and the maximum value of treatment failure are dependent on 
treatment type, drug resistance, and patient adherence to therapy. 
For simplicity, the gametocyte switching rate (GSR) was assumed to be 
uniform among asexual parasites and infections but to vary depending on the type of 
drug, and also between primary and recrudescent infections. It is assumed that all 
humans are equally attractive to biting mosquitoes and that all mosquito biting vectors 
are equally susceptible i.e. the infectiousness to mosquitoes is assumed to be 
determined solely by the gametocyte density in humans. 
To track the rate of spread of resistance, the inoculation rates of resistant and 
sensitive infections were calculated separately. Thus, the proportion of infected and 
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infectious sensitive infections is the sum of all drug - sensitive infections treated with 
different treatments multiplied by their mean infectiousness. Similarly, the proportion 
of infected and infectious drug - resistant infections is the sum of all resistant 
infections treated with different treatments multiplied by their mean infectiousness. 
Both were then divided by total number of infections (see equation 2 – 3, 
Supplementary Information B). The population with selective residual antimalarial 
drug concentrations focused on this model is the proportion with concentrations in the 
blood which prevent establishment of new drug sensitive infections but allow 
establishment of resistant infections. This proportion of population was based on 
published literature (equation 6 – 7, Supplementary Information B). 
 
Model simulations and outputs 
Malaria infections initially are all drug-sensitive and symptomatic humans receive 
only monotherapy (drug A). A steady state is defined as the point at which the number 
of new malaria cases (i.e. excluding imported cases) has varied day to day by less 
than 1% over a year. When steady state point is reached, the resistance to drug A is 
introduced, either as importation of a small number of resistant infections or by the de 
novo emergence of resistance based on available clinical and laboratory data. 
Artemisinin or its derivatives, or a completely new drug can also be introduced and 
used in a combination with drug A, or it can be used as a monotherapy. Any changes 
in malaria prevalence and levels of drug resistance thereafter are assumed to result 
from the impact of the different treatment strategies. The relationship between drug 
resistance and the maximum failure rates in a non-immune host was defined 
depending on the infection, type of treatment, and likelihood of adherence. Adherence 
is incorporated in the model by adjusting down the expected failure rates of treated 
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infections. Multiple recrudescences are treated as one continuous recrudescence, and 
overall infectiousness is calculated from the area under the gametocyte – time curve 
(AUCgam). For each model iteration, the outcomes in terms of estimated EIR, 
proportion of symptomatic infections, proportion of treatment failure, malaria 
prevalence and percentage of resistant infections are estimated for a period of 10 
years from the steady state. 
The sensitivity of the model was tested in the four baseline scenarios (scenario 
A – D). The details of fixed and variable parameters with their respective distributions 
are given in Tables A1 – A6, Supplementary information A. Each scenario is 
repeatedly run for 5,000 simulations with a unique set of parameters selected using 
the Latin Hypercube Sampling technique (LHS). The Coefficients of Variation (CVs) 
which determine the uncertainties of the model outcomes (Table A9, Supplementary 
Information C) and the Partial Rank Correlation Coefficients (PRCCs), which identify 
influential factors, were calculated (Table A10, Supplementary Information C). Full 
technical details can be found in the author’s thesis 50. 
 
Note: Supplementary information is available on the website. 
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SP, sulfadoxine - pyrimethamine; 
ACT, artemisinin combination therapy; 
GSR, gametocyte switching rate, proportion of asexual parasites committing to sexual stage 
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PRCC, partial rank correlation coefficient;  
ITN, insecticide-treated bednet 
 
Acknowledgements 
We are grateful to SMRU, KEMRI and Wellcome – Oxford – Mahosot hospital staff for 
epidemiological data. We thank Dr. Kasia Stepniewska for statistical advice, and Dr. Ric 
Price, Dr. Karen Barnes, Dr. Rebecca Freeman Grais and Dr. Lisa White for their invaluable 
comments and suggestions. Our thanks are also expressed to all staff at Mahidol – Oxford 
Tropical Medicine Research Unit.  
 
Funding 
This project was funded by Leverhulme scholarship, TDR-WHO and the Wellcome Trust of 
Great Britain’s.  
 
Competing Interests 
NJW is chairman of the WHO antimalarial treatment guidelines committee. 
 
Author Contributions 
WP developed and programmed the model and co-wrote the paper.  
SY developed the model, focusing on parameterization and co-wrote the paper. 
IH provided intellectual guidance on the mathematical modelling.  
AD provided suggestions on parasite dynamics and edited the paper. 
ND provided input on model design.  
NJW conceived of the study, provided overall intellectual guidance and edited the paper. 
 
*To whom correspondence should be addressed. E-mail: pan@tropmedres.ac 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
08
.1
53
9.
1 
: P
os
te
d 
24
 J
an
 2
00
8
    17
Figure legends 
 
Figure 1. Schematic diagram of the biological model progression from 
steady state through to the introduction of resistance and changes in 
drug policy 
 
Figure 2. The predicted spread of resistance to mefloquine when 
combined with artesunate at different level of resistance. Figure 2a 
shows the result in low transmission setting and Figure 2b shows the result in 
high transmission setting, assuming 85% coverage of the ACT (mefloquine 
and artesunate). The dotted line shows the 50% resistance. Each curve 
represents the mean of ten simulations.  
 
Figure 3. Delay in the spread of resistance to mefloquine by combining it 
with artesunate. The delay in the development of resistance is measured as 
the proportional increase in time to 50% resistance compared to the continued 
use of mefloquine as a monotherapy.  
 
Figure 4. The spread of artemisinin resistance at different levels of ACT 
coverage. Figure 4a shows the spread of artemisinin resistance at varying 
levels of ACT coverage from 0% (i.e. use of artemisinin monotherapy) to 
100% use of ACTs. Each line represents the mean of ten simulations. The 
dotted line shows the 50% resistance level. Figure 4b shows the delay in 
resistance measured as the increase in the time to 50% resistance (t50) 
compared with the t50 when using artemisinin monotherapy. The dotted line 
represents an extrapolation of the curve when the resistance does not reach 
50% within the 12-year timeframe.  
 
Figure 5. Change in malaria prevalence and incidence at different rates 
of coverage with ACT 
 
Figure 6. Schematic diagram of how immunity influences age-stratified 
likelihoods in the biological model. 
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